million Baht in 2020, and net loss of 156.50 million Baht in 2019. The Company’s net profit has increased by 645.01 million Baht or 412.16 % from the previous year. In 2020, the Company realized the after
Company’s net profit has decreased by 64.90 million Baht or 13.29 % from the previous year. In 2021, the Company realized the after adjusted EBITDA of 540.81 million Baht, and the year 2020 of 609.04 million
Thailand in 2023 growing only 1.9%, decelerating from 2.5% in the previous year, from a slowdown in public investment and public consumption due to the delay of government’s budget allocation, although the
-owned of the Listed Subsidiary 2. The Construction of Wattanapat Samui Hospital Building Contractor: Waiting 3. Buying the Medical Instruments The Company will appropriately make a purchase from
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of
period ended on March 31, 2016, as follows: Particulars Q1/2016 Q1/2015 Increase (Decrease) Million Baht Million Baht Million Baht % Revenue Revenue from selling immovable property 222.23 111.55 110.69
continually recognize revenue from EVN since commercial commencement as normal. After operation of these renewable projects, the renewable capacity portion rose to 30% from 8% while the overseas capacity
ended 30 June 2018, which net profit has changed more than 20% from the last year as follows: Statement of Comprehensive Income Unit: Million Baht 30 June 2018 30 June 2017 Increased (Decreased
marketing activities can be cause of increasing in cost of goods sold but in the long run it will emphasize FN brand awareness and increase FN brand equity. However, to dampening the impact from higher cost